×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ORMP – oramed pharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ORMP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/13
08:20 am
ormp
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company [Yahoo! Finance]
Low
Report
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company [Yahoo! Finance]
1/13
07:58 am
ormp
Oramed and Lifeward Announce Strategic Transaction
Low
Report
Oramed and Lifeward Announce Strategic Transaction
1/7
08:55 am
ormp
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Medium
Report
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
12/10
04:10 am
ormp
Oramed Pharmaceuticals (NASDAQ:ORMP) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Oramed Pharmaceuticals (NASDAQ:ORMP) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
11/17
09:05 am
ormp
Oramed Reports Fiscal Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Oramed Reports Fiscal Third Quarter 2025 Financial Results [Yahoo! Finance]
11/17
08:56 am
ormp
Oramed Reports Fiscal Third Quarter 2025 Financial Results
Low
Report
Oramed Reports Fiscal Third Quarter 2025 Financial Results
11/17
08:50 am
ormp
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
Low
Report
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
10/23
08:11 pm
ormp
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives [Yahoo! Finance]
Low
Report
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
04:07 pm
ORMP
oramed pharmaceuticals inc.
BEAT
Report
-2.9%
oramed pharmaceuticals inc.
8/14/2025
04:11 pm
ORMP
oramed pharmaceuticals inc.
BEAT
Report
-1.9%
oramed pharmaceuticals inc.
5/15/2025
04:06 pm
ORMP
oramed pharmaceuticals inc.
MISS
Report
-2.3%
oramed pharmaceuticals inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/14
04:31 pm
ormp
Form 8-K ORAMED PHARMACEUTICALS For: Jan 12
Low
Report
Form 8-K ORAMED PHARMACEUTICALS For: Jan 12
1/7
08:56 am
ormp
Form 8-K ORAMED PHARMACEUTICALS For: Jan 07
Medium
Report
Form 8-K ORAMED PHARMACEUTICALS For: Jan 07
1/5
05:22 pm
ormp
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Reznick Yehuda
Medium
Report
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Reznick Yehuda
1/5
05:21 pm
ormp
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: KIDRON NADAV
Medium
Report
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: KIDRON NADAV
1/5
05:21 pm
ormp
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Kidron Miriam
Medium
Report
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Kidron Miriam
1/5
05:21 pm
ormp
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Hexter Joshua
Medium
Report
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Hexter Joshua
1/5
05:20 pm
ormp
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Mayer Arie
Medium
Report
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Mayer Arie
1/5
05:20 pm
ormp
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Shapiro Benjamin
Medium
Report
Form 4 ORAMED PHARMACEUTICALS For: Dec 31 Filed by: Shapiro Benjamin
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/29
Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
36.2%
11/27 Form 10-K ORAMED PHARMACEUTICALS For: Aug 31 17.9%
1/9 Oramed Pharmaceuticals Issues Letter to Shareholders 14.6%
11/25 Oramed working on first insulin pill for diabetes [Yahoo! Finance News] 12.5%
3/19 Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA 11.9%
11/21 Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology 10.3%
7/15 Form 4 ORAMED PHARMACEUTICALS For: Jul 11 Filed by: Sank Leonard 7.3%
9/20 Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) was given a new $20.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 6.5%
1/28 Oramed Patent in Europe to be Granted for Oral Delivery of Proteins 4.8%
9/16 Form 4 ORAMED PHARMACEUTICALS For: Sep 12 Filed by: RAKIN KEVIN 4.3%
11/27 Form 10-K ORAMED PHARMACEUTICALS For: Aug 31 17.9%
1/9 Oramed Pharmaceuticals Issues Letter to Shareholders 14.6%
11/25 Oramed working on first insulin pill for diabetes [Yahoo! Finance News] 12.5%
3/19 Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA 11.9%
11/21 Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology 10.3%
7/15 Form 4 ORAMED PHARMACEUTICALS For: Jul 11 Filed by: Sank Leonard 7.3%
9/20 Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) was given a new $20.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 6.5%
1/28 Oramed Patent in Europe to be Granted for Oral Delivery of Proteins 4.8%
9/16 Form 4 ORAMED PHARMACEUTICALS For: Sep 12 Filed by: RAKIN KEVIN 4.3%
TOP News Decliners
11/12
Form 8-K ORAMED PHARMACEUTICALS For: Nov 12
-23.5%
2/26 Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock -11.4%
7/2 Oramed Announces Xiaoming Gao Joins Board of Directors -7.8%
11/19 Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event -7.1%
9/11 Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock. -5.2%
1/23 Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board -4.3%
10/17 Oramed Pharmaceuticals And ORMD-0901 [Seeking Alpha] -4.2%
1/30 Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board -3.9%
2/26 Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial -3.5%
5/16 Form 8-K ORAMED PHARMACEUTICALS For: May 13 -3.5%
2/26 Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock -11.4%
7/2 Oramed Announces Xiaoming Gao Joins Board of Directors -7.8%
11/19 Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event -7.1%
9/11 Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock. -5.2%
1/23 Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board -4.3%
10/17 Oramed Pharmaceuticals And ORMD-0901 [Seeking Alpha] -4.2%
1/30 Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board -3.9%
2/26 Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial -3.5%
5/16 Form 8-K ORAMED PHARMACEUTICALS For: May 13 -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: